News - Cimzia

Filter

Current filters:

Cimzia

Popular Filters

UCB files for US and EU approval for Cimzia for psoriatic arthritis and axial spondyloarthritis

20-02-2013

Belgium's largest drugmaker, UCB (Euronext Brussels: UCB) says it has made two new regulatory filings…

Anti-Arthritics/RheumaticsCimziaEuropeNorth AmericaPharmaceuticalRegulationUCB

Highlights of ACR meeting include new Cimzia, Stelara and Simponi data

13-11-2012

Belgian drugmaker UCB (UCB: BR) presented results for Cimzia (certolizumab pegol), from the Phase III…

Anti-Arthritics/RheumaticsCimziaJohnson & JohnsonPharmaceuticalResearchSimponi InjectionStelara InjectionUCB

UCB links with Astellas for Cimzia in Japan

02-02-2012

Following the recent discontinuation of a commercialization accord for its rheumatoid arthritis drug…

Anti-Arthritics/RheumaticsAsia-PacificAstellas PharmaCimziaLicensingPharmaceuticalUCB

Otsuka Pharma and UCB re-focus collaboration

16-01-2012

Japan’s Otsuka Pharmaceutical (TYO: 4768) and Belgian drugmaker UCB (Euronext Brussels: UCB) have…

Asia-PacificCimziaImmunologicalsKeppraLicensingNeurologicalOtsukaPharmaceuticalResearchrotigotineUCB

Novel ACR hybrid score in RA applied to study with UCB’s Cimzia

17-05-2011

The ACR hybrid score, a new measure of response to rheumatoid arthritis (RA) treatment recently developed…

Anti-Arthritics/RheumaticsCimziaPharmaceuticalResearchUCB

Back to top